Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - NeuroBo Pharmaceuticals, Inc. | ex-99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2017
GEMPHIRE THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-37809 |
|
47-2389984 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
17199 N. Laurel Park Drive, Suite 401
Livonia, Michigan 48152
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (248) 681‑9815
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
◻ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
◻ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
◻ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
◻ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2017, Gemphire Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2017. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
||
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
99.1 |
|
Press Release dated May 9, 2017 reporting financial results for the first quarter ended March 31, 2017. |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
GEMPHIRE THERAPEUTICS INC. |
||
|
Dated: May 9, 2017 |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Jeffrey S. Mathiesen |
|
|
|
|
|
|
|
Jeffrey S. Mathiesen |
|
|
|
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit |
Description |
|
|
99.1 |
Press Release dated May 9, 2017 reporting financial results for the first quarter ended March 31, 2017. |
|